Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Delaware Crossing Investor Group

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 12
Average round size
info
The average size of a deal this fund participated in
$3M
Portfolio companies 11
Rounds per year 0.67
Lead investments 0
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.08
Exits 3
Key employees 5
Stages of investment
Early Stage Venture
Seed

Areas of investment

  • Biotechnology
  • Health Care
  • Software
  • Manufacturing
  • Pharmaceutical
Summary

Delaware Crossing Investor Group is the famous VC, which was founded in 2005. The fund was located in North America if to be more exact in United States. The main department of described VC is located in the Doylestown.

Among the most popular fund investment industries, there are Health Care, Biotechnology. The fund has no exact preference in some founders of portfolio startups. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Annovis Bio, Novira Therapeutics For fund there is a match between the location of its establishment and the land of its numerous investments - United States.

The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Delaware Crossing Investor Group, startups are often financed by BioAdvance, Robin Hood Ventures, Ben Franklin Technology Partners of Southeastern Pennsylvania. The meaningful sponsors for the fund in investment in the same round are Robin Hood Ventures, Mid Atlantic Angel Fund, BioAdvance. In the next rounds fund is usually obtained by Rockies Venture Club, Robin Hood Ventures, BioAdvance.

Besides them, we counted 5 critical employees of this fund in our database.

The fund is constantly included in less than 2 deals per year. The common things for fund are deals in the range of 1 - 5 millions dollars. The top activity for fund was in 2011. The top amount of exits for fund were in 2015. This Delaware Crossing Investor Group works on 9 percentage points less the average amount of lead investments comparing to the other organizations.

Read more

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Alpen Route Asset Management Seoul, Seoul-t'ukpyolsi, South Korea
Asian asset management -
Chengdu City Wealth Chengdu, China, Sichuan
Chilin Venture Capital -
CIT VentureCapital Morristown, New Jersey, United States
Daoyitong Beijing, Beijing, China
Harmonic Growth Partners Chevy Chase, Maryland, United States
Lautman Foundation -
McKinney Durham, North Carolina, United States
Tiempo France, Montbonnot-saint-martin, Rhone-Alpes

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Measure Studio

21 Apr 2023 Los Angeles, California, United States

ThruPore Technologies

Chemical
Industrial
Manufacturing
$540K21 Feb 2018 Delaware, United States

Only Sky

Hotel
Service Industry
Software
Travel
$420K07 Jun 2017 Denver, Colorado, United States

Life.io

FinTech
Health Care
$1M12 Jan 2016 Philadelphia, Pennsylvania, United States

Annovis Bio

Biotechnology
Developer Platform
Therapeutics
$5M26 May 2015 Easttown Township, Pennsylvania, United States

Hulafrog

Events
Internet
Local
Parenting
$500K22 May 2013 New Jersey, United States

Novira Therapeutics

Biotechnology
Health Care
Pharmaceutical
$25M24 Mar 2013 Radnor Township, Pennsylvania, United States

Novira Therapeutics

Biotechnology
Health Care
Pharmaceutical
$2M26 Jul 2009 Radnor Township, Pennsylvania, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Delaware Crossing Investor Group?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 12
Average round size 3M
Rounds per year 0.67
Peak activity year 2013
Lead investments 0
Follow on index 0.08
Exits 3
Group Appearance index 1.00

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Measure Studio

21 Apr 2023 Los Angeles, California, United States

ThruPore Technologies

Chemical
Industrial
Manufacturing
$540K21 Feb 2018 Delaware, United States

Only Sky

Hotel
Service Industry
Software
Travel
$420K07 Jun 2017 Denver, Colorado, United States

Life.io

FinTech
Health Care
$1M12 Jan 2016 Philadelphia, Pennsylvania, United States

Annovis Bio

Biotechnology
Developer Platform
Therapeutics
$5M26 May 2015 Easttown Township, Pennsylvania, United States

Hulafrog

Events
Internet
Local
Parenting
$500K22 May 2013 New Jersey, United States

Novira Therapeutics

Biotechnology
Health Care
Pharmaceutical
$25M24 Mar 2013 Radnor Township, Pennsylvania, United States

Novira Therapeutics

Biotechnology
Health Care
Pharmaceutical
$2M26 Jul 2009 Radnor Township, Pennsylvania, United States
Crunchbase icon

Content report

The following text will be sent to our editors: